We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
- Authors
Jubb, Adrian M; Hurwitz, Herbert I; Bai, Wei; Holmgren, Eric B; Tobin, Patti; Guerrero, A Steven; Kabbinavar, Fairooz; Holden, Scott N; Novotny, William F; Frantz, Gretchen D; Hillan, Kenneth J; Koeppen, Hartmut
- Abstract
Bevacizumab is a monoclonal antibody to vascular endothelial growth factor-A (VEGF). In the pivotal trial in metastatic colorectal cancer (mCRC), addition of bevacizumab to first-line irinotecan, fluorouracil, and leucovorin (IFL) significantly prolonged median survival. The aim of these retrospective subset analyses was to evaluate VEGF, thrombospondin-2 (THBS-2), and microvessel density (MVD) as prognostic factors and/or predictors of benefit from bevacizumab.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Vol 24, Issue 2, p217
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2005.01.5388